A BTK inhibitor combined with standard R-CHOP produced rapid, PET-defined complete remission in high-risk DLBCL-type Richter syndrome with TP53 deletion. Delaying ibrutinib until cycle 2 was used as a ...

Jan 5 (Reuters) - Incyte (INCY.O), opens new tab said on Monday its experimental combo therapy helped patients with a type of blood cancer live longer without their disease worsening in a late-stage ...

Several factors contribute to the development of DLBCL, including genetic predispositions, infections, and environmental exposures. The disease usually presents with generalized lymphadenopathy, and ...

PHILADELPHIA (WPVI) -- A miracle baby who was treated with a pioneering gene-therapy at Children's Hospital of Philadelphia has reached a major milestone as he took his first steps. KJ Muldoon was the ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Brian T. Hill, MD, PhD, discusses promising results from a study examining the impact ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Brian T. Hill, MD, PhD, discusses a study presented at ASH Annual Meeting and ...

As the American Society of Hematology (ASH)’s annual conference wraps up this week, Regeneron is using it as an opportunity to tout its hematology pipeline — and early data on two blood cancer drugs.

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester ...

Epcoritamab combined with R-mini-CHOP showed a 93% overall response rate in elderly DLBCL patients, with 86% achieving complete response. At two years, 79% of patients remained in response, and 90% ...

Odronextamab combined with CHOP chemotherapy shows high efficacy in untreated DLBCL, with a 100% response rate at the 160 mg dose. The safety profile of odronextamab-CHOP is manageable, with common ...

(UroToday.com) The 2025 ESMO annual meeting featured a urothelial carcinoma proffered paper session and a presentation by Dr. Enrique Grande discussing DISCUS, a phase 2 study comparing 3 versus 6 ...